Intralesional methotrexate treatment for keratoacanthoma tumors: a retrospective case series

Abstract

Background: Intralesional methotrexate (IL-MTX) is an effective treatment for keratoacanthoma.

Objective: We sought to determine the response rates and adverse events in KA treated with intralesional methotrexate.

Methods: All cases of KA treated with intralesional methotrexate at our institutions from 2001 to 2009 were systematically reviewed.

Results: Forty-six cases of KA treated with IL-MTX were identified. A complete resolution was achieved in 74% of patients, requiring an average of 1.8 injection sessions, for a mean total dose of 10 mg. Adverse events did not occur.

Limitations: The follow-up period was short, and there was no histologic confirmation of the initial diagnosis.

Conclusion: IL-MTX is an effective and well-tolerated alternative to surgery for the treatment of KA.